CXCL8 and neoplasm: IL-8 positivity in tumor infiltrate was also independently associated with a lower risk of disease recurrence (HR for relapse-free survival (RFS): 0.55, CI: 0.36–0.85, p < 0.001); median RFS was indeed not reached in stage II-III CRC patients whose tumors displayed an IL-8 positive infiltrate, as compared to a median RFS of 69 months in patients with no IL-8 immunoreactivity in their tumor infiltrate (p < 0.01 by log-rank test).